P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML

• J. Senapati,
• F. Haddad,
• F. Ravandi,
• T. Kadia,
• C. DiNardo,
• N. Daver,
• N. Pemmaraju,
• Y. Alvarado,
• M. A. Brandt,
• H. Kantarjian,
• G. Borthakur

Affiliations

J. Senapati

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

F. Haddad

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

F. Ravandi

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

T. Kadia

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

C. DiNardo

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

N. Daver

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

N. Pemmaraju

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

Y. Alvarado

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

M. A. Brandt

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

H. Kantarjian

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

G. Borthakur

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America